Dianthus Therapeutics (DNTH)

• Market cap: $5.16B
• 1 day: -5.55%
• 5 days: -5.1%
• 1 month: 19.62%
• 3 months: 1.57%
• 6 months: 113.97%
• Year to date: 137.8%
• 1 year: 375.6%
• 5 years: -33.29%
• 10 years: -59.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Employees: 92